首页 / 院系成果 / 成果详情页

Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the In Vitro Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa 期刊论文

编号：

0956549e-daff-41ce-acfc-c946e8a8ac2d
作者：

Yin, Dandan#^[1,2]Wu, Shi(吴湜)#^[1,2]Yang, Yang^[1,2];Shi, Qingyu^[1,2];Dong, Dong^[1,2];Zhu, Demei(朱德妹)^[1,2]Hu, Fupin(胡付品)*^[1,2]
语种：

英文
期刊：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY ISSN：0066-4804 2019 年 63 卷 4 期 ; APR
收录：
关键词：

Enterobacteriaceae Pseudomonas aeruginosa bla(KPC) bla(NDM) ceftazidime-avibactam ceftolozane-tazobactam multicenter study
摘要：

The in vitro activities of ceftazidime-avibactam (CZA), ceftolozane-tazobactam (C-T), and comparators were determined for 1,774 isolates of Enterobac-teriaceae and 524 isolates of Pseudomonas aeruginosa collected by 30 medical centers from the China Antimicrobial Surveillance Network (CHINET) in 2017. Antimicrobial susceptibility testing was performed by the CLSI broth microdilution method, and bla(KPC) and bla(NDM) were detected by PCR for all carbapenem-resistant Enterobacteriaceae (CRE). Ceftazidime-avibactam demonstrated potent activity against almost all Enterobacteriaceae (94.6% susceptibility; MIC50, <= 0.25 mg/liter; MIC90, <= 0.25 to >32 mg/liter) and good activity against P. aeruginosa (86.5% susceptibility; MIC50/90, 2/16 mg/liter). Among the CRE, 50.8% (189/372 isolates) were positive for bla(KPC)-2, which mainly existed in ceftazidime-avibactam-susceptible Klebsiella pneumoniae isolates (92.1%, 174/189). Among the CRE, 17.7% (66/372 isolates) were positive for bla(NDM), which mainly existed in strains resistant to ceftazidime-avibactam (71.7%, 66/92). Ceftolozane-tazobactam showed good in vitro activity against Escherichia coli and Proteus mirabilis (MIC50/90, <= 0.5/2 mg/liter; 90.5 and 93.8% susceptibility, respectively), and the rates of susceptibility of K. pneumoniae (MIC50/90, 2/>64 mg/liter) and P. aeruginosa (MIC50/90, 1/8 mg/liter) were 52.7% and 88.5%, respectively. Among the CRE strains, 28.6% of E. coli isolates and 85% of K. pneumoniae isolates were still susceptible to ceftazidime-avibactam, but only 7.1% and 1.9% of them, respectively, were susceptible to ceftolozane-tazobactam. The rates of susceptibility of the carbapenem-resistant P. aeruginosa isolates to ceftazidime-avibactam (65.7%) and ceftolozane-tazobactam (68%) were similar. Over-all, both ceftazidime-avibactam and ceftolozane-tazobactam were highly active against clinical isolates of Enterobacteriaceae and P. aeruginosa recently collected across China, and ceftazidime-avibactam showed activity superior to that of ceftolozane-tazobactam against Enterobacteriaceae, whereas ceftolozane-tazobactam showed a better effect against P. aeruginosa.
推荐引用方式
GB/T 7714：

Yin Dandan,Wu Shi,Yang Yang, et al. Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the In Vitro Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa [J].ANTIMICROBIAL AGENTS AND CHEMOTHERAPY,2019,63(4).
APA：

Yin Dandan,Wu Shi,Yang Yang,Shi Qingyu,&Hu Fupin.(2019).Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the In Vitro Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa .ANTIMICROBIAL AGENTS AND CHEMOTHERAPY,63(4).
MLA：

Yin Dandan, et al. "Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the In Vitro Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa" .ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 63,4(2019).
条目包含文件：

文件类型：PDF,文件大小：

正在加载全文

未找到全文

浏览次数：17  下载次数：0

分享到：

浏览次数：17

下载次数：0

打印次数：0